NeoGenomics - Serving Patients. Saving Lives.
We at NeoGenomics were thrilled to be a part of the 2023 ASCO® Annual Meeting in Chicago. We met so many incredible colleagues from all over the globe, we presented several abstracts with new data from our RaDaR® assay for MRD and with your support we were able to raise $10,000 for Conquer Cancer®, the ASCO Foundation. If you visited us in our booth, you saw that Neo is for cancer patients. We have impacted the lives of well over 200,000 patients just this year. We are excited to have you with us on our journey to transform the lives of 1 million patients by 2028.
NeoGenomics and Collaborators' Abstracts Poster Presentations
NeoGenomics, alongside collaborators, are excited to present new data from our RaDaR® MRD and Liquid Biopsy technology. The posters are available for download on our website.
RaDaR Minimal Residual Disease (MRD)
The RaDaR assay is a personalized test for minimal residual disease (MRD) and recurrence detection. RaDaR can detect microscopic levels of ctDNA with 10-fold higher sensitivity than other leading MRD tests. RaDaR MRD testing is validated for use in multiple solid tumor cancers. Learn more at FinditwithRaDaR.com
NeoAccess
NeoGenomics is proud to announce the launch of NeoAccess™ at ASCO.
Created specifically for oncologists, NeoAccess provides built-in clinical decision support to simplify and streamline evidence-based biomarker testing into a single, time-saving, easy-to-use online ordering experience. Additionally, the platform provides visibility into patient insurance benefits and estimates out-of-pocket costs in real time.
To learn more and schedule a demo, visit: neogenomics.com/neoaccess